<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03498170</url>
  </required_header>
  <id_info>
    <org_study_id>MBCT103</org_study_id>
    <nct_id>NCT03498170</nct_id>
  </id_info>
  <brief_title>The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants</brief_title>
  <official_title>An Open-label, 2-period, Single-sequence, Crossover Study to Evaluate the Effect of Multiple Oral Dosing of Itraconazole on BCT197 Systemic Exposure in Healthy Male Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mereo BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mereo BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-label, 2-period, Single-sequence, Crossover Study to Evaluate the Effect of Multiple
      Oral Dosing of Itraconazole on BCT197 Systemic Exposure in Healthy Male Participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an open label study conducted in healthy male participants at a single centre.
      Each participant will participate in a screening visit and 2 study periods. At the first
      study period, all participants will receive a single dose of BCT197 and at study period 2,
      all participants will receive 14 daily doses of itraconazole and a single dose of BCT197.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 19, 2018</start_date>
  <completion_date type="Actual">May 9, 2018</completion_date>
  <primary_completion_date type="Actual">May 3, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Measurable Plasma Concentration (Cmax) BCT197 in the presence and absence of itraconazole.</measure>
    <time_frame>Pre-dose to Day 15</time_frame>
    <description>Period 1: Pre-dose and 1, 2, 4, 6, 12, 24, 36, 48, 72, 96, 144 and 168 hours post BCT197 dose on Day 1.
Period 2: Pre-dose and 1, 2, 4, 6, 12, 24, 36, 48, 72, 96, 144, 168 and 192 hours post BCT197 dose on Day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) BCT197 in the presence and absence of itraconazole.</measure>
    <time_frame>Pre-dose to Day 15</time_frame>
    <description>Period 1: Pre-dose and 1, 2, 4, 6, 12, 24, 36, 48, 72, 96, 144 and 168 hours post BCT197 dose on Day 1.
Period 2: Pre-dose and 1, 2, 4, 6, 12, 24, 36, 48, 72, 96, 144, 168 and 192 hours post BCT197 dose on Day 7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of adverse events during administration of BCT197 alone and in the presence of itraconazole.</measure>
    <time_frame>Day 1 to Day 21</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Corrected QT interval of the electrocardiogram (QTc).</measure>
    <time_frame>Pre-dose to Day 15</time_frame>
    <description>Period 1: Pre-dose, 2, 4, 6, 8, 24 and 168 hours post BCT197 dose on Day 1. Period 2: Pre-dose, 2, 4, 6, 8, 24, 168 and 192 hours post BCT197 dose on Day 7.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Interaction</condition>
  <arm_group>
    <arm_group_label>Period 1 and Period 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1 - BCT197 14mg on Day 1
Period 2 - itraconazole 200mg on Day 1 to 14 and BCT197 14mg on Day 7</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCT197</intervention_name>
    <description>Single dose of BCT197</description>
    <arm_group_label>Period 1 and Period 2</arm_group_label>
    <other_name>Acumapimod</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole 200 mg</intervention_name>
    <description>Single dose of itraconazole</description>
    <arm_group_label>Period 1 and Period 2</arm_group_label>
    <other_name>Sporanox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male participants.

          -  Non-smokers (including e-cigarettes).

          -  Body mass index (BMI) ≥ 18 and ≤ 30 kg/m2.

          -  Willing to use highly effective barrier contraception methods.

          -  Male participants must not donate sperm during the study.

        Exclusion Criteria:

          -  Any participants with pre-existing active skin disease.

          -  Laboratory values at screening which are deemed to be clinically significant.

          -  Participants with abnormal liver function tests.

          -  12 Lead ECG with QTcF &gt;450 msec.

          -  Allergy to any of BCT197 excipients.

          -  Known hypersensitivity or intolerance to itraconazole.

          -  Taking medications known to cause QTc prolongation.

          -  Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C.

          -  Any clinically significant illness within 30 days prior to study drug administration.

          -  Participants who, in the opinion of the Investigator, are unsuitable for participation
             in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacqueline Parkin, PhD FRCP</last_name>
    <role>Study Director</role>
    <affiliation>Mereo BioPharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>inVentiv Health Clinical Research Services LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2018</study_first_submitted>
  <study_first_submitted_qc>April 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2018</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Male Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

